Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on July 26, 2018, to announce its financial results for the second quarter of 2018. This filing primarily directs investors to a press release (Exhibit 99.1) and supplemental information on the company's website (Exhibit 99.2) for detailed financial performance and operational updates during the quarter. While the 8-K itself doesn't contain the specific financial figures or operational highlights, it signifies the official release of the company's quarterly performance. Investors should review the furnished exhibits, particularly the press release and supplemental data, to understand BMY's revenue, earnings, product performance, and any strategic developments announced for the second quarter of 2018.
Key Highlights
- 1BMY filed an 8-K on July 26, 2018, to report on its second-quarter 2018 financial results.
- 2The primary purpose of the filing is to furnish a press release announcing the company's Q2 2018 financial performance.
- 3A press release, dated July 26, 2018, is attached as Exhibit 99.1 and incorporated by reference.
- 4Supplemental financial information, not included in the press release, is also furnished as Exhibit 99.2.
- 5Investors are directed to review Exhibits 99.1 and 99.2 for detailed financial results and operational updates.
- 6The filing indicates that the Q2 2018 earnings call or release occurred around July 25-26, 2018.